Comparative safety of concurrent adjuvant trastuzumab emtansine vs trastuzumab with radiotherapy in HER2-positive early breast cancer
Abstract Background Real-world comparative data on the safety of adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab with concurrent radiotherapy (RT) in HER2-positive early breast cancer (BC) remain limited. Methods In this retrospective, multicenter study, we included 133 patients with HER2-positive early-stage BC...